Goldman Sachs’s Genomic Health, Inc. GHDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-265,344
Closed -$18M 5548
2019
Q3
$18M Sell
265,344
-425,638
-62% -$29.2M 0.01% 1867
2019
Q2
$40.2M Sell
690,982
-87,817
-11% -$5.2M 0.01% 1302
2019
Q1
$54.6M Buy
778,799
+120,763
+18% +$8.95M 0.02% 1041
2018
Q4
$42.4M Sell
658,036
-11,738
-2% -$823K 0.01% 1213
2018
Q3
$47M Buy
669,774
+54,572
+9% +$3.19M 0.01% 1266
2018
Q2
$31M Buy
615,202
+193,197
+46% +$7.67M 0.01% 1574
2018
Q1
$13.2M Buy
422,005
+17,762
+4% +$589K ﹤0.01% 2129
2017
Q4
$13.8M Sell
404,243
-45,513
-10% -$1.45M ﹤0.01% 2208
2017
Q3
$14.4M Buy
449,756
+78,950
+21% +$2.49M ﹤0.01% 2261
2017
Q2
$12.1M Buy
370,806
+76,758
+26% +$2.43M ﹤0.01% 2356
2017
Q1
$9.26M Buy
294,048
+81,425
+38% +$2.41M ﹤0.01% 2471
2016
Q4
$6.25M Buy
212,623
+41,405
+24% +$1.26M ﹤0.01% 2858
2016
Q3
$4.95M Buy
171,218
+59,161
+53% +$1.65M ﹤0.01% 3053
2016
Q2
$2.9M Buy
112,057
+30,191
+37% +$802K ﹤0.01% 3300
2016
Q1
$2.03M Buy
81,866
+51,635
+171% +$1.42M ﹤0.01% 3455
2015
Q4
$1.06M Sell
30,231
-83,525
-73% -$2.24M ﹤0.01% 4232
2015
Q3
$2.41M Sell
113,756
-155,933
-58% -$4.02M ﹤0.01% 3612
2015
Q2
$7.49M Buy
269,689
+165,155
+158% +$4.66M ﹤0.01% 2584
2015
Q1
$3.19M Sell
104,534
-41,586
-28% -$1.32M ﹤0.01% 3331
2014
Q4
$4.67M Buy
146,120
+5,055
+4% +$165K ﹤0.01% 3060
2014
Q3
$3.99M Buy
141,065
+69,724
+98% +$1.94M ﹤0.01% 3237
2014
Q2
$1.95M Buy
71,341
+2,361
+3% +$62.8K ﹤0.01% 4017
2014
Q1
$1.82M Sell
68,980
-104,537
-60% -$3M ﹤0.01% 4068
2013
Q4
$5.08M Sell
173,517
-13,109
-7% -$416K ﹤0.01% 3067
2013
Q3
$5.71M Sell
186,626
-14,788
-7% -$495K ﹤0.01% 2800
2013
Q2
$6.39M Buy
+201,414
New +$6.62M ﹤0.01% 2501

Goldman Sachs's GHDX Position: Q4 2019 in Review

Goldman Sachs sold out of Genomic Health, Inc. (GHDX) in Q4 2019, closing a stake of 265,344 shares — an estimated $18M sold.

Goldman Sachs first reported a position in GHDX in Q2 2013 and held it in 26 quarters. The position peaked at $54.6M in Q1 2019. 0 funds tracked by Wall St. Rank hold GHDX as of Q4 2019.

  • Goldman Sachs reported no remaining Genomic Health, Inc. position as of Q4 2019 after selling out during the quarter.
  • Goldman Sachs sold 265,344 Genomic Health, Inc. shares in Q4 2019, an estimated $18M.
  • Goldman Sachs first reported a position in Genomic Health, Inc. in Q2 2013 and held it in 26 quarters.
  • Goldman Sachs's Genomic Health, Inc. position peaked at $54.6M in Q1 2019.
  • 0 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2019.

Based on Goldman Sachs's 13F filing for Q4 2019, filed 14 Feb 2020.